Сайты международных организаций Здесь вы сможете найти больше материалов на русском и других языках по теме безопасного аборта. Международный консорциум по медикаментозному аборту http://www.medicalabortionconsortium.org/resources.html Международная Ассоциация Профессионалов в области Абортов и Контрацепции http://fiapac.org/e/Links1.html Проект Gynuity Health Proejct http://gynuity.org/pub.html  Публикации о мизопростоле Winikoff B. Global overview of medical abortion. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17-20 October 2004, Johannesburg. non CS, Winikoff B. (editors). Misoprostol: An emerging technology for women's health. Report of a seminar. New York, Population Council, 2004. www.medicalabortion.org/questions/work.html, referred on 25 May 2005 World Health Organization. Safe abortion: Technical and policy guidelines for health systems. Geneva, WHO, 2003. Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. National Evidence-Based Clinical Guidelines. London: RCOG, September 2004. Summary at: www.rcog.org.uk/resources/Public/pdf/abortion_summary.pdf. Accessed 27 October 2005. Mifiprex (mifepristone) medication guide. www.fda.gov/cder/drug/infopage/mifepristone/medguide.htm. Referred on 15 June, 2005. Information on ectopic pregnancy from www.medicinenet.com/ectopic_pregnancy/article.htm. Referred on 10 June, 2005. Hill NC, Selinger M, Ferguson J et al. The placental transfer of mifepristone during the second trimester and its influence upon maternal and fetal steroid concentrations. British Journal of Obstetrics and Gynaecology, 1990, 97:406-411. Vogel D, Burkhardt T, Rentsch K et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. American Journal of Obstetrics and Gynecology, 2004, 191:2168-2173. de Bruyn M. Safe abortion for HIV-positive women with unwanted pregnancy: A reproductive right. Reproductive Health Matters, 2003; Vol.11 No. 22: 52-61. Gynuity. Providing medical abortion in developing countries: An introductory guidebook. New York, Gynuity Health Projects, 2004. Berer M. Medical abortion: Issues of choice and acceptability. Reproductive Health Matters 2005;13(26):25-34): Ganatra B. Contrasts and Common Ground: The Context of Abortion in Asia. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17-20 October 2004, Johannesburg, South Africa Elul B, Peralman E, Sorhaindo A, et al. In-depth interviews with medical abortion clients: Thoughts on the method and home administration of Misoprostol. Journal of the American Medical Women's Association Volume 55, no. 3 supplement 2000 pp 169-172. Information on pregnancy tests from www.4woman.gov/faq/pregtest.htm, referred on 10 June, 2005. www.medicationabortion.org/questions/index.html referred on 15 May, 2005 with inputs from ICMA Steering Committee members and reviewers. von Hertzen H, Nguyen H, Piaggio G, et al. Comparison of two routes and two intervals of administration of misoprostol for the termination of early pregnancy: a randomised multicentre trial. Interim results (unpublished) Clinical Guidelines: medical abortion 13-20 weeks. London: bpas, 2005. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200mg for abortion up to 63 days of pregnancy. Contraception 2002;66:247-50 Hamoda H, Ashok PW, Flett G, et al. Medical abortion at 9-13 weeks' gestation: a review of 1,076 consecutive cases. Contraception 2005;71:327-32. Consensus Statement: Instructions for use - Abortion induction with misoprostol in pregnancies up to 9 weeks LMP. Expert Meeting on misoprostol sponsored by Reproductive Health Technologies Project and Gynuity Health Projects. July 28, 2003, Washington D.C. Fiala C, Swahn ML, Stephansson O, et al. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. Human Reproduction 2005;Aug 11 (Abstract only, e-publication). Jain JK, Dutton C, Harwood B et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction 2005;17(6):1477-1482. www.ppnyc.org/services/factsheets/mifep.htm referred on 2 June, 2005. US Food and Drug Administration. FDA Alert for Healthcare Professionals: Mifepristone (marketed as Mifeprex), 22 July 2005. At: and . Accessed 29 August 2005. Shannon C, Brothers LP, Philip NM, et al. Infection after medical abortion: a review of the literature. Contraception 2004;70:183-90. Fischer M, Bhatnagar J, Guarner J et al. Fatal toxic shock syndrome associated with clostridium sordellii after medical abortion. New England Journal of Medicine 2005;353: 2352?2360. Greene MF. Fatal infections associated with mifepristone-induced abortion. New England Journal of Medicine 2005;353: 2317?2318. Grimes DA. Risk of mifepristone in context [Commentary]. Contraception 2005;71:161. Chen A, Yuan W, Meirik O et al. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. American Journal of Epidemiology 2004;160(2):110-117.